SCHEMBL2127253

SCHEMBL2127253

Cc1cccc(C(F)(F)F)c1S(=O)(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
TSHR P16473 1/20 0.42
SLC9A1 P19634 1/20 0.38
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPT P10636 2/20 0.36
HSD11B1 P28845 2/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8409325 0.98 MEN1 (0.41) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL795355 0.88 MEN1 (0.41) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL4279665 0.83 GABRA1 (0.52) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL28231669 0.83 MEN1 (0.43) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL28113278 0.81 MEN1 (0.42) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL8409006 0.81 MEN1 (0.42) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL10405821 0.81 NPSR1 (0.44) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL8409324 0.80 KMT2A (0.41) MEN1KMT2ACYP1A2CYP3A4CYP2C19
Fluoromethane SCHEMBL27938455 0.80 ALDH1A1 (0.40) CYP1A2CYP3A4TSHRSLC9A1ALDH1A1
Formic Acid SCHEMBL28234886 0.80 KDM4E (0.39) MEN1KMT2ACYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452223-B2 Materials and methods relating to glycosylation GLYTHERA LIMITED (GB) 2016-09-27 US claimed
EP-2442831-B9 Materials and methods relating to glycosylation of a therapeutic polypeptide GLYTHERA LTD (GB) 2016-05-11 EP claimed
EP-2442831-B1 Materials and methods relating to glycosylation of a therapeutic polypeptide GLYTHERA LTD (GB) 2015-11-04 EP claimed
CN-102481377-B Materials and methods relating to glycosylation THE UNIVERSITY OF BATH (GB) 2014-10-29 CN claimed
US-20120190631-A1 MATERIALS AND METHODS RELATING TO GLYCOSYLATION Iksuda Therapeutics Limited (GB) 2012-07-26 US claimed
CN-102481377-A Materials and methods relating to glycosylation UNIV BATH 2012-05-30 CN claimed
EP-2442831-A2 MATERIALS AND METHODS RELATING TO GLYCOSYLATION The University Of Bath (GB) 2012-04-25 EP claimed
WO-2010146362-A2 MATERIALS AND METHODS RELATING TO GLYCOSYLATION THE UNIVERSITY OF BATH (GB) 2010-12-23 WO claimed
US-9452223-B2 Materials and methods relating to glycosylation GLYTHERA LIMITED (GB) 2016-09-27 US disclosed
EP-2442831-B9 Materials and methods relating to glycosylation of a therapeutic polypeptide GLYTHERA LTD (GB) 2016-05-11 EP disclosed
EP-2442831-B1 Materials and methods relating to glycosylation of a therapeutic polypeptide GLYTHERA LTD (GB) 2015-11-04 EP disclosed
CN-102481377-B Materials and methods relating to glycosylation THE UNIVERSITY OF BATH (GB) 2014-10-29 CN disclosed
US-20120190631-A1 MATERIALS AND METHODS RELATING TO GLYCOSYLATION Iksuda Therapeutics Limited (GB) 2012-07-26 US disclosed
CN-102481377-A Materials and methods relating to glycosylation UNIV BATH 2012-05-30 CN disclosed
EP-2442831-A2 MATERIALS AND METHODS RELATING TO GLYCOSYLATION The University Of Bath (GB) 2012-04-25 EP disclosed
WO-2010146362-A2 MATERIALS AND METHODS RELATING TO GLYCOSYLATION THE UNIVERSITY OF BATH (GB) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190631-A1 MATERIALS AND METHODS RELATING TO GLYCOSYLATION NEU3, FUT5, NEU2 MEN1 1699/4885KMT2A 2832/4885CYP1A2 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.